Cybin Secures $175M to Advance Psychedelic Depression Trials
As mental health treatment developers seek funding to advance clinical programs through late-stage trials, psychedelic medicine companies face particular scrutiny over their path to commercialization. Cybin Inc., a Toronto-based neuropsychiatry company, recently closed a $175 million registered direct offering to […]
Cybin Secures $175M to Advance Psychedelic Depression Trials Read More »










